Cite
HARVARD Citation
Mallory, R. et al. (2022). Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet infectious diseases. 22 (11), pp. 1565-1576. [Online].